SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (3854)2/19/1998 3:19:00 PM
From: Steve Fancy  Respond to of 6136
 
AGPH is looking great again, in a down market no less. About to break that magic 40. Must have been a one day breather while the scrip data was evaluated.

My previous post was my first attempt at scanning a fax with a combination ink jet/copier/scanner/fax that I corrected manually. Please excuse typo's and formatting problems...I noticed that on the last two tables the tabs messed up on Norvir.

Any feedback on this data from the more experienced here?

sf



To: Steve Fancy who wrote (3854)2/19/1998 5:03:00 PM
From: Peter Singleton  Respond to of 6136
 
Steve, thanks for posting the PW update.

Two numbers to keep our eyes on would be the Norvir scrip # (as EW points out, giving an indication of Norvir + saquinavir hgc/sgc prescriptions), and especially the combined number for Roche's Invirase and Fortovase. Viracept has been edging up in market share about a point a month. If Fortovase takes off, Viracept's market share growth may stall. It's hard to tell from the data so far.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News